Skip to the lineages
Regenerative Medicine

What Role Do Growth Factors Play in Tissue Repair?

Published November 16, 2026

Protocol: 6 steps in this guide
  1. What a growth factor is
  2. PDGF, TGF-beta and VEGF in plain language
  3. Signaling in early vs late wound phases
  4. Where platelets release signaling proteins
  5. Concentration and timing uncertainties
  6. Why in-vitro effects may not predict trials

Growth factors are signaling proteins that tell cells when to move into an injury, when to multiply, when to build new blood vessels and when to lay down new matrix. They coordinate repair rather than doing it themselves, and each one acts at particular stages. That is also why adding more of them from outside, for example in an injection, is not the same as guaranteeing better healing: timing, balance and the tissue involved all matter.

What a growth factor is

A 2026 review in Current Diabetes Reviews, An Overview and Review of Growth Factors in Wound Healing, describes growth factors as orchestrating the events of healing “by regulating cell migration, proliferation, differentiation, and extracellular matrix synthesis.” It names PDGF, TGF-beta, VEGF, FGF and EGF among the mediators of wound healing and states that these factors “act in a coordinated manner” across hemostasis, inflammation, proliferation and remodeling.

Two points follow from that description. Growth factors are messengers, so their effect depends on which cells receive the message and when. And they work as a set, so no single factor is “the” healing factor.

PDGF, TGF-beta and VEGF in plain language

The glossary below links each factor to a function and a stage, using only what the cited reviews say.

Growth factor What it does, per the cited reviews When it is described as active Source
PDGF (platelet-derived growth factor) Released by platelets on injury; stimulates migration and proliferation of fibroblasts and smooth muscle cells and promotes granulation tissue. In tendon, has "a powerful cell chemotaxis" and promotes cell proliferation Early, after injury Wound and tendon reviews
TGF-beta (transforming growth factor beta) Regulates inflammation, collagen deposition and remodeling. In tendon, described as promoting cell proliferation and inhibiting the inflammatory response Wound review: across phases. Tendon review: "almost during the entire phase of tendon healing" Wound and tendon reviews
VEGF (vascular endothelial growth factor) Promotes new blood vessel formation to supply oxygen and nutrients Tendon review: "immediately after injury" Wound and tendon reviews
IGF-1 (insulin-like growth factor 1) In tendon, stimulates cell division while suppressing the inflammatory response Tendon review: "immediately after injury" Tendon review

The tendon entries come from a 2023 review in International Wound Journal, Current progress in growth factors and extracellular vesicles in tendon healing, which states plainly that different growth factors “are active at various stages of healing and exhibit separate physiological activities.”

Signaling in early vs late wound phases

The same factor can help at one point and cause trouble at another. The tendon review notes that VEGF accelerates local metabolism by promoting blood vessel formation early on, but that “VEGF’s protracted action could be harmful to tendon healing.” It also describes PDGF as able to “accelerate the response to inflammation.”

The wound review makes the general version of that point: “Dysregulation of growth factor expression or signaling can impair the healing process, leading to chronic wounds or excessive scar formation.” Healing depends on the right signal at the right time, not on the maximum amount of signal. The phases themselves are described in what happens during the stages of soft tissue healing, and what happens when inflammation does not resolve is covered in how chronic inflammation affects tissue healing.

Where platelets release signaling proteins

Platelets are one source. The American Academy of Orthopaedic Surgeons explains in its patient page on platelet-rich plasma that platelets, best known for clotting, “also contain hundreds of proteins called growth factors that are very important in the healing of injuries.” The wound review describes PDGF specifically as “released by platelets upon injury.”

This is the idea behind platelet-rich plasma: concentrate platelets, and you concentrate the growth factors they carry. AAOS says the platelet concentration in PRP can be 5 to 10 times greater than usual. How the preparation is made is covered in how platelet-rich plasma is made from a blood sample, and how platelets are triggered to release their contents in what PRP activation is and when it is used.

Concentration and timing uncertainties

Concentrating platelets does not produce a standard dose of growth factors. A 2025 review in Acta Biomaterialia by Rath and colleagues, Platelet-rich plasma – A comprehensive review of isolation, activation, and application, which examines PDGF, VEGF and TGF-beta among other platelet factors, states: “Variability in factors such as platelet and leukocyte content, red blood cell contamination, and activation methods complicates the clinical implementation and standardization of platelet-rich products.” It adds that PRP’s “clinical outcomes remain inconsistent due to variability in preparation and application methods.”

Clinical analyses reflect that uncertainty. A 2026 meta-regression of placebo-controlled knee osteoarthritis trials (Delgado and colleagues, Knee Surgery, Sports Traumatology, Arthroscopy) found that a higher platelet increase factor and activation with calcium chloride were associated with better six-month results, but rated the evidence certainty as very low, noted that PRP characteristics were correlated with one another, and described its findings as “hypothesis-generating rather than definitive evidence supporting specific PRP formulations.” That question is examined in whether platelet concentration changes PRP treatment outcomes.

Why in-vitro effects may not predict trials

What a growth factor does to cells in a dish, or in an animal model, is evidence about mechanism. It does not show that injecting a growth-factor-rich product into a person’s joint or tendon will improve healing. AAOS makes the same distinction for PRP: laboratory studies suggest the increased concentration of growth factors “may potentially speed up the healing process,” yet “it is not exactly clear how PRP works.”

Three gaps separate the lab from the clinic:

  1. Timing. The tendon review describes factors that help early and can harm if prolonged; an injection delivers a dose at one moment, not a timed sequence.
  2. Mixture. A platelet preparation delivers many factors at once, in amounts that vary between products, as the Rath review describes.
  3. Outcome. A trial has to show that patients improve compared with a control group. Mechanistic reviews, including the ones cited here, do not test that.

Condition-by-condition clinical evidence for PRP is reviewed separately, for example in what the evidence says about PRP for knee osteoarthritis.

Growth factors are the signals that coordinate repair, each with its own job and timing, so more of them is not the same as better healing; whether a growth-factor product helps a given condition is a question for controlled trials, not for biology alone.

Cells linked to this one

This guide leads on to

Guides that lead here

Lineage A: Regenerative Biology

What readers added

Add a remark

Your email address will not be published. Required fields are marked *